Abbott (ABT) SVP Eric Shroff granted options and performance stock

Rhea-AI Filing Summary

Abbott Laboratories Senior Vice President Eric Shroff reported equity awards that increase his direct holdings. He received an option for 44,821 shares at an exercise price of $0.00 and a grant of 10,873 common shares, both characterized as awards or other acquisitions.

The 10,873-share grant is a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program with a three-year term and no more than one-third vesting in any year, tied to a minimum return on equity target. The 44,821-share employee stock option, also under the 2017 program, becomes exercisable in annual increments of 14,940 shares on February 24, 2027 and February 24, 2028, and 14,941 shares on February 24, 2029.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shroff Eric

Role Senior Vice President

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	44,821	$0.00	--
Grant/Award	Common shares without par value	10,873	$0.00	--

Holdings After Transaction: Option (right to buy) — 44,821 shares (Direct); Common shares without par value — 41,257 shares (Direct)

Footnotes (1)

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,940 on February 24, 2027, 14,940 on February 24, 2028, and 14,941 on February 24, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shroff Eric

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		10,873(1)	A	$0	41,257	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(2)	$114.6	02/24/2026		A		44,821		02/24/2027	02/23/2036	Common Shares	44,821	$0	44,821	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,940 on February 24, 2027, 14,940 on February 24, 2028, and 14,941 on February 24, 2029.

	/s/ Eric Shroff by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Abbott (ABT) executive Eric Shroff receive?

Eric Shroff received an option for 44,821 Abbott shares and a grant of 10,873 common shares. Both are awards under the Abbott Laboratories 2017 Incentive Stock Program, increasing his direct equity exposure through performance-based restricted stock and time-vesting stock options.

How do Eric Shroff’s new Abbott (ABT) stock options vest?

The 44,821-share employee stock option vests in three equal annual installments. It becomes exercisable for 14,940 shares on February 24, 2027, 14,940 shares on February 24, 2028, and 14,941 shares on February 24, 2029, subject to the program’s standard terms.

What are the terms of Eric Shroff’s performance-based Abbott (ABT) stock award?

The 10,873-share award is performance-based restricted stock with a three-year term. No more than one-third can vest in any year, and vesting depends on Abbott reaching a minimum return on equity target, aligning potential share delivery with company performance over time.

Does Eric Shroff’s Abbott (ABT) stock award allow tax withholding in shares?

Yes. The performance-based restricted stock award includes the right to have shares withheld for tax purposes. This means a portion of vested shares can be retained by Abbott to satisfy tax obligations instead of requiring separate cash payments by the executive.

Are Eric Shroff’s Abbott (ABT) equity awards under a specific incentive plan?

Both the stock option and the performance-based restricted stock award were granted under the Abbott Laboratories 2017 Incentive Stock Program. The option grant is described as exempt from Section 16 under Rule 16b-3, reflecting its status as a compensation-related employee award.